The vaccine manufacturer said its own trial, between 3,235 participants, listed 12 COVID-19 instances that surfaced starting 14 days after the initial dose. The business said it hadn’t identified any critical security concerns thus far.
The outcomes of the teenage trial come since the Food and Drug Administration (FDA) is expected to provide emergency use consent for its Pfizer-BioNTech vaccine for use among 12- to 15-year-olds at the forthcoming days.
Pfizer and BioNTech discovered their vaccine to be 100 percent successful among the 12-15 age group in study published last month.
Contrary to Moderna’s vaccine, the Pfizer-BioNTech vaccine has FDA emergency consent to be awarded to 16- and 17-year-olds.
However, the producers are taking measures to find emergency approval for kids and teens. Moderna announced it began testing the shots on kids aged six months to 12 years last month also stated on Thursday that research is continuing.
Last week, Pfizer told reporters it expects to get completed studies on kids aged 2 to 11 and employ for emergency use authorization in September.
Moderna released the results of its teen trial together with its first quarter earnings report, where the firm said it had its own first profitable quarter.
The vaccine maker recorded $1.7 billion in annual revenue from merchandise sales with a net earnings of $1.2 billion. This past year, Moderna reported that a $124 million net reduction during this quarter.